Compare Novo Nordisk A/S (NVO) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Charles Schwab Corporation Common Stock — how do they compare? Novo Nordisk A/S trades at $38.38 (market cap $165.31B), while Charles Schwab Corporation Common Stock trades at $97.01 (market cap $167.52B). The key difference: Novo Nordisk A/S and Charles Schwab Corporation Common Stock are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| NVO | SCHW | |
|---|---|---|
Market Cap | $165.31B | $167.52B |
Volume | 11,432,838 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $63.98 | $113.65 |
52-Week Low | $35.29 | $85.35 |
Typical Hold Time | 116 Days | 85 Days |
Enterprise Value | $179.56B | $153.97B |
Dividend Yield | 4.71% | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Charles Schwab (SCHW) trades at $96.80, up 1.28% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 17.64, net income margin of 38.79%, and robust cash flow. Recent news highlights growth in client assets to $13.41 trillion and a strategic AI partnership with Anthropic.
The outlook is positive with a consensus price target of $120.33, implying significant upside. Risks include competitive pressures and market volatility, but strong earnings momentum and a favorable industry growth forecast support a bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
